Acyclic And Contains At Least One Carbon Atom Between The Phosphorus Atoms Patents (Class 514/108)
-
Publication number: 20120171303Abstract: Compositions comprising melatonin and one or more carotenoids and methods for using such compositions for enhancing cognitive and related functions such as reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, improving attention, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, and preventing or treating cognitive decline caused by dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.Type: ApplicationFiled: September 2, 2010Publication date: July 5, 2012Inventors: Brian Michael Zanghi, Ziad Saad Ramadan
-
Publication number: 20120164239Abstract: A composition for treating wood-based material including at least one C1-C7 monocarboxylic acid salt or C1-C7 monocarboxylic acid or a mixture thereof as active agent against deteriation of wood. The composition also includes alkyd emulsion of high unsaturated fatty acid content and/or aluminum ion containing compound in the form of polyaluminum formate in a same aqueous liquid carrier as the C1-C7 monocarboxylic acid salt or C1-C7 monocarboxylic acid or a mixture thereof.Type: ApplicationFiled: November 25, 2009Publication date: June 28, 2012Inventors: Juha Estakari, Toivo Mertaniemi, Jari Jussila, Juha Kuusisto, Reijo Saunamäki, Norberto Mancuso
-
Publication number: 20120142641Abstract: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.Type: ApplicationFiled: June 7, 2010Publication date: June 7, 2012Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Subramanian Venkatraman, Say Chye Joachim Loo
-
Publication number: 20120128780Abstract: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.Type: ApplicationFiled: October 17, 2011Publication date: May 24, 2012Inventors: Gary G. Liversidge, Scott Jenkins
-
Publication number: 20120121502Abstract: The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.Type: ApplicationFiled: November 15, 2011Publication date: May 17, 2012Applicant: ACETYLON PHARMACEUTICALSInventors: John H. van Duzer, Ralph Mazitschek, Yanbing Ding, Nan Yu, Yun Cao, Yong Liu
-
Patent number: 8178712Abstract: The present invention relates to an improved process for the synthesis of Ibandronate sodium of formula (I). The present invention also provides novel processes for the synthesis of 3-[N-(methylpentyl)amino]propionic acid (III).Type: GrantFiled: June 22, 2007Date of Patent: May 15, 2012Assignee: Cipla Ltd.Inventors: Dharamaraj Ramchandra Rao, Rajendra Narayanrao Kankan, Maruti Ganpati Ghagare
-
Publication number: 20120114731Abstract: A multilayer protein film has a mass of greater than 0.5 ?g/cm2 and consists essentially of protein. A drug delivery device comprises the multilayer protein film onto which a pharmaceutically active agent can be loaded. A biomedical implant comprises an implant substrate and the multilayer protein film on at least a portion of the implant substrate surface. A method of making a multilayer protein film having a mass of greater than 0.5 ?g/cm2 comprises contacting a substrate with a protein solution at a temperature of from about 30° C. to about 95° C., wherein a multilayer protein film having a mass of greater than 0.5 ?g/cm2 is formed on the substrate.Type: ApplicationFiled: May 24, 2010Publication date: May 10, 2012Applicant: ADDBIO ABInventors: Ella Cathrine Vikinge, Elin Engström, Henrik Aronsson, Oskar Axelsson
-
Publication number: 20120107323Abstract: The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof.Type: ApplicationFiled: March 12, 2010Publication date: May 3, 2012Applicant: University of FloridaInventors: Steven N. Hochwald, David A. Ostrov, William G. Cance, Elena Kurenova
-
Publication number: 20120093914Abstract: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens.Type: ApplicationFiled: November 24, 2009Publication date: April 19, 2012Applicant: MOMA THERAPEUTICSInventor: Shai Yehoshua Schubert
-
Publication number: 20120093748Abstract: Topical compositions are provided that have 0.5% or more of at least one personal care or pharmaceutical acid, and lightly- to moderately-crosslinked PVP, which is an effective thickener in the low pH systems. In preferred embodiments, the acid is a hydroxy acid and the composition used for personal care, or prescriptive or non-prescriptive medication indications for use on the skin, hair, scalp, foot, or lips. Also provided is the use of the topical compositions to deliver the acid(s) to the skin, hair, scalp, foot, or lips. Especially preferred is a use to reduce irritation and stinging compared to an equivalent compositions not having lightly- to moderately-crosslinked PVP.Type: ApplicationFiled: March 11, 2010Publication date: April 19, 2012Applicant: ISP INVESTMENTS INC.Inventors: Hani Fares, Chris Barrett, Tracey Ross, Anthony Luschen
-
Patent number: 8153588Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: June 23, 2010Date of Patent: April 10, 2012Assignee: NPS Pharmaceuticals, Inc.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjögren
-
Publication number: 20120076770Abstract: THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone marrow, and bone tissue.Type: ApplicationFiled: March 28, 2011Publication date: March 29, 2012Inventors: Virginia Espina, Lance Liotta, Antonella Chiechi, Alessandra Romano, Emanuel Petricoin, Amy Van Meter
-
Patent number: 8143236Abstract: Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents. In addition compositions and methods for mitigating or preventing a novel form of chemotherapy-induced peripheral neuropathy are disclosed and claimed.Type: GrantFiled: March 14, 2008Date of Patent: March 27, 2012Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Publication number: 20120070469Abstract: Nanoparticulate assemblies of isolated ?-casein are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. The nanoparticulate assemblies can be freeze-dried and re-suspended prior to administration.Type: ApplicationFiled: August 18, 2011Publication date: March 22, 2012Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Yechezkel BARENHOLZ, Dganit Danino
-
Publication number: 20120064088Abstract: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition.Type: ApplicationFiled: September 9, 2011Publication date: March 15, 2012Applicant: Wisconsin Alumni Research FoundationInventors: Dai Yamanouchi, K. Craig Kent, Bo Liu
-
Publication number: 20120065166Abstract: THE INVENTION RELATES TO compositions, compounds, proteins and methods of treatment therewith. Aspects of embodiments also relate to a method of treating a patient by delivering to the tissues of said patient or administering to said patient a therapeutically effective amount of one or more compounds. Aspects of embodiments also relate to a method of detecting the presence of bone disease by machine-assaying detectable serotonin. Aspects of embodiments also relate to methods of treating disease in subjects.Type: ApplicationFiled: August 15, 2011Publication date: March 15, 2012Inventors: Virginia Espina, Lance Liotta, Antonella Chiechi, Alessandra Romano
-
Publication number: 20120035138Abstract: A bisphosphonate is formulated with an agent to reduce surface tension and/or reduce foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance.Type: ApplicationFiled: October 13, 2011Publication date: February 9, 2012Applicant: SELAMINE LIMITEDInventors: Paul Jonathan Harrison, Anna Marie Power
-
Publication number: 20120028926Abstract: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.Type: ApplicationFiled: January 26, 2010Publication date: February 2, 2012Applicant: CYTOCHROMA INC.Inventors: Uttam Saha, Christian F. Helvig, P. Martin Petkovich
-
Publication number: 20110311616Abstract: Provided herein are compositions including particles that comprise a bisphosphonate compound and a tumor specific targeting peptide or peptidomimetic. Also provided herein are methods of reducing tumor associated macrophages and methods of treating cancer with said compositions.Type: ApplicationFiled: June 16, 2011Publication date: December 22, 2011Inventors: Jeff Smith, Gaurav Sharma
-
Publication number: 20110311602Abstract: Microbial growth inhibiting solutions and methods of employing the microbial growth inhibiting solutions in flushing and coating medical devices are disclosed. In alternative embodiments, the microbial growth inhibiting solutions include combinations of a chelating agent with a C4-C9 carboxylate antimicrobial agent, for example, such as n-octanoic acid. Methods of using these microbial growth inhibiting solutions for coating a medical device and for inhibiting catheter infection are also disclosed.Type: ApplicationFiled: August 31, 2011Publication date: December 22, 2011Applicant: Organic Medical Ventures, L.L.C.Inventors: Stanley L. Mills, Jacqueline L. Mills, Robert D. Maurer, Gary L. Rayburn, Marvin A. Cuchens
-
Publication number: 20110286937Abstract: The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the glycolipid includes a plant ceramide portion and a sugar chain portion; and B) mixing the provided glycolipid with a liposome raw material and subjecting the mixture to conditions in which a liposome is formed.Type: ApplicationFiled: February 18, 2009Publication date: November 24, 2011Applicants: GIFU UNIVERSITY, KATAYAMA CHEMICAL INDUSTRIES CO., LTD.Inventors: Makoto Kiso, Hideharu Ishida, Taiji Yamashita, Koichi Igarashi, Masahiko Hirai
-
Publication number: 20110275581Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.Type: ApplicationFiled: June 13, 2011Publication date: November 10, 2011Applicants: University of Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
-
Publication number: 20110262528Abstract: The invention relates to medicine and pharmacology, and represents a pharmaceutical composition for the treatment of bone resorption of various etiology comprising, as the biologically active ingredient, liposomes with biphosphonates in gel dosage form suitable for transdermal delivery of biphosphonates and effective local therapy. Using this composition, methods for the prevention and treatment of osteoporosis, Paget's disease, patoplogical fractures associated with oncological diseases, and some other pathological processes associated with bone resorption and reparation are proposed.Type: ApplicationFiled: March 18, 2008Publication date: October 27, 2011Inventors: Aleksander Vladimirovich Dikovskiy, Boris Anatolievich Rudoi, Oleg Valentinovich Dorozhko
-
Publication number: 20110251144Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: September 16, 2009Publication date: October 13, 2011Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20110236365Abstract: Methods and compositions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds.Type: ApplicationFiled: May 17, 2011Publication date: September 29, 2011Applicant: HealthPartners Research FoundationInventors: William H. Frey, II, John Randall Fawcett
-
Publication number: 20110237552Abstract: The invention relates to novel composite materials based on a collagen matrix mineralised with silicate and calcium phosphate phases, to a method for the production thereof and use thereof as an implant material which can be shaped in a plurality of ways, a biological coating or active substance carrier. The claimed composite material comprises a collagen matrix which is mineralised with silicate and a calcium phosphate phase, said collagen being a recombinate collagen, collagen from Eumetazoa, sponge collagen from a sponge of the Demospongia class (horn sponges) or Calcarea (calcareous sponges), a synthetic collage analogue, a collagen derivative or a mixture of said collagens.Type: ApplicationFiled: September 11, 2009Publication date: September 29, 2011Applicant: TECHNISCHE UNIVERSITAET DRESDENInventors: Sascha Heinemann, Hartmut Worch, Thomas Hanke
-
Patent number: 8026227Abstract: Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.Type: GrantFiled: December 13, 2006Date of Patent: September 27, 2011Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Publication number: 20110224128Abstract: The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.Type: ApplicationFiled: April 13, 2010Publication date: September 15, 2011Inventors: Anne Whalen, Jane Staunton, Janine Steiger, Amy B. Wilson, Yang Wu
-
Patent number: 8008329Abstract: The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis.Type: GrantFiled: July 31, 2009Date of Patent: August 30, 2011Assignee: Dong Wha Pharmaceutical Co., Ltd.Inventors: Jei Man Ryu, Jin Soo Lee, Yun-Ha Hwang, Young G. Jin, Ki Y. Kim
-
Publication number: 20110182985Abstract: The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.Type: ApplicationFiled: January 26, 2011Publication date: July 28, 2011Inventors: David C. Coughlan, Thomas W. Leonard, Bozena Adamczyk, Kieran Madigan, Edel O'Toole, Alan Cullen, Jason O'Hara
-
Publication number: 20110183905Abstract: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.Type: ApplicationFiled: August 11, 2009Publication date: July 28, 2011Inventor: Karin Schönhammer
-
Publication number: 20110178044Abstract: Methods, formulations, and drug delivery systems are provided for enhancing the flux of a transdermally administered hydrophilic drug using a basic permeation enhancer composition. The enhancer composition contains an inorganic hydroxide and a weaker, nitrogenous base, wherein the bases are selected such that a 0.1M aqueous solution of the nitrogenous base has a pH that is about 1.0 to about 6.5 lower than the pH of a 0.1M aqueous solution of the inorganic hydroxide. Additionally, the molar ratio of the nitrogenous base to the inorganic hydroxide in the enhancer composition is in the range of about 0.5n:1 to about 20n:1, where n is the number of hydroxide ions per molecule of the inorganic hydroxide.Type: ApplicationFiled: April 4, 2011Publication date: July 21, 2011Inventors: Tsung-Min Hsu, Eric Jacobson, Eric C. Luo, Alan T.J. Hickey, Nicole T. Gricenko
-
Publication number: 20110165092Abstract: The subject matter of the invention is a cosmetic and/or dermatological composition for use in the treatment of skin and/or hair disorders. More particularly, the invention relates to a cosmetic and/or dermatological composition comprising an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of farnesyl pyrophosphate synthase, or an inhibitor of one of the physiologically acceptable salts thereof and a cosmetic and/or dermatological product. The present invention finds, for example, a very advantageous use in the treatment of the effects of early ageing, in particular in terms of the skin and the hair system.Type: ApplicationFiled: December 31, 2008Publication date: July 7, 2011Applicant: Universite de la Mediterranee, Aix-Marseille IIInventors: Pierre Cau, Patrice Bourgeois, Vincent Bonniol, Nicolas Levy
-
Publication number: 20110166107Abstract: Methods of and kits for determining the pharmacogenetic, pharmacokinetic and cellular basis of bisphosphonate-induced osteonecrosis of the jaw (BONJ) involve associating particular proteins and particular single nucleotide polymorphisms with a risk for developing BONJ after receiving bisphosphonate treatment. Methods and kits for identifying the genetic basis for a patient's predisposition to BONJ, and methods of identifying patients who are prone to develop BONJ following bisphosphonate administration provide for the development of a tool for physicians to prescribe treatment protocols for BONJ patients based on the patients' genomes (“personal/tailored medicine”).Type: ApplicationFiled: July 7, 2009Publication date: July 7, 2011Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: Joseph Katz, Taimour Y. Langaee
-
Publication number: 20110152220Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.Type: ApplicationFiled: March 30, 2009Publication date: June 23, 2011Inventors: Gerard Karsenty, Patricia F. Ducy, Yuli Xie, Donald Landry, Vijay Kumar Yadav
-
Publication number: 20110142904Abstract: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.Type: ApplicationFiled: February 22, 2011Publication date: June 16, 2011Applicant: Synthes USA, LLCInventor: Maria Maccecchini
-
Publication number: 20110112053Abstract: Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods relate generally to the use of compositions that inhibit RhoA GTPase levels or activity, such as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.Type: ApplicationFiled: April 16, 2009Publication date: May 12, 2011Applicant: University of Utah Research FoundationInventors: Dean Li, Kevin Whitehead, Aubrey Chan, Nyall London, Sutip Navankasattusas
-
Publication number: 20110112054Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: ApplicationFiled: January 17, 2011Publication date: May 12, 2011Applicant: BIOAGENCY AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Publication number: 20110105435Abstract: The present invention relates to the use of a bisphosphonate derivative according to general Formula I and/or a pharmaceutically acceptable salt thereof, wherein R1 and/or R2 are independently selected out of a group comprising hydrogen, hydroxyl, halogen, pseudohalogen, formyl, carboxy- and/or carbonyl derivatives, alkyl, long-chain alkyl, alkoxy, long-chain alkoxy, cycloalkyl, halogenalkyl, aryl, arylene, halogenaryl, heteroaryl, heteroarylene, heterocycloalkylene, heterocycloalkyl, halogenheteroaryl, alkenyl, halogenalkenyl, alkinyl, halogenalkinyl, keto, ketoaryl, halogenketoaryl, ketoheteroaryl, ketoalkyl, halogenketoalkyl, ketoalkenyl, halogenketoalkenyl, phosphoalkyl, phosphonate, phosphate, phosphine, phosphine oxide, phosphoryl, phosphoaryl, suiphonyl, sulphoalkyl, sulphoarenyl, sulphonate, sulphate, sulphone, amine, polyether, silylalkyl, silylalkyloxy, and wherein at appropriate residues one or more non-adjacent CH2-groups may be replaced independently from each other with —O—, —S—, —NH—, —NRoType: ApplicationFiled: November 4, 2008Publication date: May 5, 2011Inventors: Holger Köhler, Rainer Pooth
-
Publication number: 20110098252Abstract: The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.Type: ApplicationFiled: December 8, 2010Publication date: April 28, 2011Applicant: New York UniversityInventor: Marco Pappagallo
-
Patent number: 7932241Abstract: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.Type: GrantFiled: September 17, 2004Date of Patent: April 26, 2011Assignee: Novartis AGInventors: Alexandra Glausch, Rolf Löffler, Juergen Sigg
-
Patent number: 7928091Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: GrantFiled: July 5, 2006Date of Patent: April 19, 2011Assignee: Merck Frosst Canada Ltd.Inventors: Cameron Black, Sheldon Crane, Renata Oballa, Joel Robichaud
-
Patent number: 7915239Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4) alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4)alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.Type: GrantFiled: November 28, 2003Date of Patent: March 29, 2011Assignee: Ceva Sante AnimaleInventors: Philippe Du Mesnil, Thierry Bardon, Dominique Thibaud
-
Publication number: 20110065672Abstract: The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is alendronate, and it is covalently bonded to either tartaric acid or glyceric acid.Type: ApplicationFiled: September 16, 2010Publication date: March 17, 2011Applicants: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, LEHIGH UNIVERSITYInventors: ALEXANDER KIRSCHENBAUM, ALICE C. LEVINE, STEVEN L. REGEN, VACLAV JANOUT
-
Publication number: 20110052703Abstract: Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the beta-casein micelles may be used to administer the agents to the GI tract for treatment of local or systemic conditions. These carriers are stable over a wide temperature range (optionally at least from about 1° C. to at least about 45° C.).Type: ApplicationFiled: February 11, 2009Publication date: March 3, 2011Inventors: Yechezkel Barenholz, Dganit Danino
-
Publication number: 20110046091Abstract: This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.Type: ApplicationFiled: December 31, 2008Publication date: February 24, 2011Applicant: UNIVERSITE DE LA MEDIERANNEE, AIX-MARSEILLE II JARDIN DU PHARO 58, BOULEVARD CHARLES LIVONInventors: Pierre Cau, Patrice Bourgeois, Vincent Bonniol, Nicolas Levy
-
Publication number: 20110033505Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: ApplicationFiled: August 16, 2010Publication date: February 10, 2011Applicant: RELYPSA, INC.Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
-
Patent number: 7875597Abstract: The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.Type: GrantFiled: July 21, 2003Date of Patent: January 25, 2011Inventor: Marco Pappagallo
-
Publication number: 20110014265Abstract: A bone implant comprises an active agent on at least a portion thereof. The active agent is locally deliverable to bone proximate the implant in at least a two-phased release scheme. A first phase rapidly releases a first quantity of the active agent, and at least a second phase gradually releases a second quantity of the active agent, whereby bone formation stimulated by the active agent is modulated. In one embodiment, a porous implant comprises a porous portion coated with a calcium phosphate compound and which is contacted with a bisphosphonate compound to form a bisphosphonate layer chemically bound to the calcium phosphate at the surface of the porous portion and to form bisphosphonate molecules being non-chemically attached inside the pores of the porous portion. The non-chemically attached bisphosphonate molecules are released in the subject at a rate greater than that of the chemically bound bisphosphonate layer.Type: ApplicationFiled: September 24, 2010Publication date: January 20, 2011Inventors: John Dennis Bobyn, Michael Tanzer
-
Publication number: 20110015120Abstract: Pharmaceutical and cosmetic compositions for topical use comprising Lactoferrin, Ciclopirox and/or salts thereof, Etidronic Acid and/or salts thereof and use of said compositions in the treatment of dermatological disorders and conditions such as seborrheic dermatitis and dandruff.Type: ApplicationFiled: June 17, 2010Publication date: January 20, 2011Applicant: VALETUDO S . r . l .Inventor: Vittorino Bortolin